Factory building

Advance toward new horizons in retinal care

Meet our team

Meet our team

Mission

Our mission is to improve vision by advancing the reach of retinal therapies where unmet needs for patients and physicians persist.

Our mission is to improve vision by advancing the reach of retinal therapies where unmet needs for patients and physicians persist.

IMVIONIX Inc. is a privately held ophthalmology biotechnology company focused on advancing the delivery of retinal therapies. Founded in 2025, IMVIONIX identifies, develops, and commercializes promising treatments that patients and physicians need but cannot reach.

Scientist in laboratorium

Beliefs

Closing the gap between promise and patients

Closing the gap between promise and patients

We believe that many promising retinal therapies and innovations lack the resources needed to reach the patients who could benefit from them most. We help close the gap by investing in both earlier-stage programs and commercial-stage therapeutics designed to improve visual outcomes while working with others who share our commitment to putting these beliefs into practice.

Beliefs

Closing the gap between promise and patients

We believe that many promising retinal therapies and innovations lack the resources needed to reach the patients who could benefit from them most. We help close the gap by investing in both earlier-stage programs and commercial-stage therapeutics designed to improve visual outcomes while working with others who share our commitment to putting these beliefs into practice.

Leadership

Advancing access through visionary leadership

Advancing access through visionary leadership

Our founders bring deep experience building ophthalmology brands, with a proven track record in retinal disease. As the team behind Alimera Sciences, they successfully commercialized retinal therapies that fulfilled unmet needs and improved outcomes before leading the company through its acquisition in 2024.

Rick Eiswirth

Founder, President and CEO

Rick has served as a CFO, COO, and President, leading asset acquisitions, strategic development, and commercial growth across the retina category. As the CEO of Alimera Sciences, he led the commercialization of ILUVIEN® and YUTIQ®, which culminated in a ~$425M sale of the company in 2024.

Jason Werner

Chief Operating Officer

Jason is a seasoned pharmaceutical executive with more than 20 years of experience in the ophthalmic industry. His career has been defined by building operational excellence and leading business development activity through strategic growth and transformative exits.

Todd Wood

Chief Commercial Officer

Todd brings a proven track record of commercial leadership in retina and ophthalmology, having launched and grown major brands, built and led high-performing teams, and cultivated deep, lasting relationships across the eye care community.

Elliot Maltz

Chief Financial Officer

Elliot brings 20 years of accounting and financial leadership with a strong track record of optimizing global financial operations for biopharmaceutical companies, developing organizational infrastructure, and executing strategic transactions across public and private companies.

Board of Directors

Rick Eiswirth

Rick serves on the Board of Directors, bringing decades of leadership experience in the ophthalmic industry and a proven track record of guiding strategy, growth, and execution. He also brings a full-spectrum view of how to build and scale a commercial ophthalmology business.

Rick serves on the Board of Directors, bringing decades of leadership experience in the ophthalmic industry and a proven track record of guiding strategy, growth, and execution. He also brings a full-spectrum view of how to build and scale a commercial ophthalmology business.

David Johnson

David brings extensive board experience, serving as a director of Liquidia Corp. and Exelixis, Inc., and previously as a board member of AMAG Pharmaceuticals, the Children's Scholarship Fund, and the Harvard College Fund. Prior to that, he held senior investment roles at The Carlyle Group, Morgan Stanley, and Weiss Asset Management.

worker on laboratorium

Approach

Leveraging a commercial platform to empower the retina community

Leveraging a commercial platform to empower the retina community

We support both earlier-stage programs with the potential to shape the future of retinal care and commercial-stage assets that can make an immediate difference. From expanding the reach of approved therapies to helping promising innovations move forward, every decision we make is guided by the same goal: advancing therapies for the retina community to improve outcomes for the patients they serve. Through this approach, we help create lasting opportunities for growth and impact across the retina community.

Get in touch

Have a question or want to connect with our team? Please complete the form below and we’ll route your inquiry to the appropriate contact.